Profund Advisors LLC Buys 5,338 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Profund Advisors LLC lifted its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 73.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,638 shares of the biotechnology company’s stock after purchasing an additional 5,338 shares during the period. Profund Advisors LLC’s holdings in United Therapeutics were worth $4,026,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Symmetry Investments LP purchased a new stake in United Therapeutics in the second quarter worth $669,000. Ensign Peak Advisors Inc lifted its position in shares of United Therapeutics by 27.2% during the 2nd quarter. Ensign Peak Advisors Inc now owns 33,677 shares of the biotechnology company’s stock valued at $10,728,000 after buying an additional 7,205 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of United Therapeutics by 19.6% during the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock worth $178,972,000 after acquiring an additional 92,240 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in United Therapeutics by 47.6% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 87,370 shares of the biotechnology company’s stock worth $27,832,000 after acquiring an additional 28,192 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its stake in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Up 0.5 %

Shares of NASDAQ UTHR opened at $353.00 on Friday. The business has a 50-day moving average of $339.19 and a 200-day moving average of $291.68. The firm has a market capitalization of $15.66 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The company had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. During the same period in the previous year, the company earned $5.24 EPS. United Therapeutics’s quarterly revenue was up 19.8% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

Insider Activity at United Therapeutics

In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total value of $2,821,050.45. Following the completion of the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $348.41, for a total transaction of $93,722.29. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $45,293.30. The disclosure for this sale can be found here. Insiders have sold a total of 110,922 shares of company stock valued at $36,541,398 over the last 90 days. 12.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on UTHR. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. UBS Group lifted their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research note on Monday, July 8th. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Bank of America reduced their price target on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $350.36.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.